Equities research analysts expect Prothena Corporation PLC (NASDAQ:PRTA) to post $440,000.00 in sales for the current quarter, Zacks reports. Five analysts have issued estimates for Prothena Corporation PLC’s earnings, with the lowest sales estimate coming in at $230,000.00 and the highest estimate coming in at $1.00 million. Prothena Corporation PLC reported sales of $290,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 51.7%. The business is expected to announce its next earnings report on Tuesday, November 7th.

On average, analysts expect that Prothena Corporation PLC will report full-year sales of $440,000.00 for the current fiscal year, with estimates ranging from $27.50 million to $31.19 million. For the next year, analysts anticipate that the business will post sales of $43.97 million per share, with estimates ranging from $1.56 million to $101.20 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Prothena Corporation PLC.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.43. The firm had revenue of $26.81 million during the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The firm’s quarterly revenue was up 7951.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.18) earnings per share.

PRTA has been the topic of several analyst reports. Zacks Investment Research upgraded Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Friday, August 11th. BidaskClub downgraded Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC initiated coverage on Prothena Corporation PLC in a report on Monday, July 10th. They set a “buy” rating and a $100.00 price objective on the stock. BTIG Research initiated coverage on Prothena Corporation PLC in a report on Friday, May 19th. They set a “buy” rating and a $80.00 price objective on the stock. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Prothena Corporation PLC in a report on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $77.58.

TRADEMARK VIOLATION NOTICE: “Prothena Corporation PLC (PRTA) Expected to Announce Quarterly Sales of $440,000.00” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/13/prothena-corporation-plc-prta-expected-to-announce-quarterly-sales-of-440000-00.html.

In other news, Director Dennis J. Selkoe sold 3,500 shares of Prothena Corporation PLC stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $58.11, for a total value of $203,385.00. Following the completion of the transaction, the director now owns 6,345 shares in the company, valued at approximately $368,707.95. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Karin L. Walker sold 5,000 shares of Prothena Corporation PLC stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at approximately $324,450. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Woodford Investment Management Ltd grew its position in shares of Prothena Corporation PLC by 2.6% in the 2nd quarter. Woodford Investment Management Ltd now owns 11,400,424 shares of the biotechnology company’s stock worth $616,991,000 after acquiring an additional 294,213 shares in the last quarter. FMR LLC grew its position in shares of Prothena Corporation PLC by 0.7% in the 2nd quarter. FMR LLC now owns 5,699,234 shares of the biotechnology company’s stock worth $308,443,000 after acquiring an additional 39,926 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Prothena Corporation PLC by 4.6% in the 1st quarter. Wellington Management Group LLP now owns 3,158,012 shares of the biotechnology company’s stock worth $176,185,000 after acquiring an additional 138,979 shares in the last quarter. BlackRock Inc. grew its position in shares of Prothena Corporation PLC by 7.8% in the 2nd quarter. BlackRock Inc. now owns 2,947,512 shares of the biotechnology company’s stock worth $159,519,000 after acquiring an additional 213,578 shares in the last quarter. Finally, State Street Corp grew its position in shares of Prothena Corporation PLC by 10.6% in the 2nd quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock worth $63,932,000 after acquiring an additional 113,193 shares in the last quarter.

Shares of Prothena Corporation PLC (NASDAQ:PRTA) traded down 0.18% during trading on Wednesday, reaching $62.27. The company had a trading volume of 59,372 shares. Prothena Corporation PLC has a 52-week low of $40.58 and a 52-week high of $69.53. The firm has a 50-day moving average price of $59.72 and a 200-day moving average price of $56.03. The company’s market capitalization is $2.38 billion.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Get a free copy of the Zacks research report on Prothena Corporation PLC (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.